Neoadjuvant treatment of biliary tract cancer: state-of-the-art and new perspectives.

IF 1.2 Q4 ONCOLOGY

Hepatic Oncology Pub Date : 2016-01-01 Epub Date: 2015-11-30 DOI:10.2217/hep.15.43

Marco Imperatori, Loretta D'Onofrio, Eleonora Marrucci, Francesco Pantano, Alice Zoccoli, Giuseppe Tonini

引用次数: 10

Abstract

Gall bladder cancer (GBC), and intrahepatic and extrahepatic (perihilar or distal bile duct's) cholangiocarcinomas (CCA) are usually diagnosed in locally advanced or node-positive stage, with a short survival rate. Thus, it appears essential to explore novel strategies for improving disease downstage and radical surgery. Chemoradiotherapy followed by liver transplantation seems to be one of the most promising approaches for intrahepatic or perihilar disease while chemotherapy with novel radiotherapy techniques (such stereotactic body radiation) emerged as an attractive preoperative treatment in distal diseases. In this paper, we will review currently available knowledge about neoadjuvant treatment of biliary tract cancers (BTC) paying attention to challenges that make this type of management in clinical practice difficult.

Abstract Image

查看原文本刊更多论文

胆道癌的新辅助治疗:最新的和新的观点。

胆囊癌(GBC)和肝内、肝外(肝门周围或远端胆管)胆管癌(CCA)通常诊断为局部晚期或淋巴结阳性，生存率较短。因此，探索改善晚期疾病和根治性手术的新策略显得至关重要。放化疗后肝移植似乎是肝内或肝门周围疾病最有前途的方法之一，而化疗结合新型放疗技术(如立体定向体辐射)成为远端疾病的一种有吸引力的术前治疗方法。在本文中，我们将回顾目前关于胆道肿瘤(BTC)新辅助治疗的现有知识，并关注使这种管理在临床实践中困难的挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.